Circio logoCircio logo

  • About
      • About Circio
      • CEO Statement
      • Pipeline
      • Management Team
      • Board of Directors
      • Careers
      • The Norwegian Transparency Act
  • circRNA
      • Circio AB
      • circVec platform
  • Clinical programs
      • KRAS program
      • Publications
  • Partnering
  • Investors
      • Press releases
      • Events
      • Financial calendar
      • Reports
      • Presentations
      • Prospectus
      • Share facts
      • Largest shareholders
      • Dividend policy
      • Analyst coverage
      • Registrar and auditor
      • Corporate Governance Policy
      • Code of Conduct
      • Corporate Social Responsibility Principles
      • Remuneration Principles
      • About General Meeting
        • General Meetings
      • Articles of Association
      • Board of Directors
        • Nomination Committee
        • Committees
      • Management
      • Contact
  • Media
      • Press releases
      • Events
      • Subscribe
      • Contact
  • Contacts
    • About
      • About Circio
      • CEO Statement
      • Our pipeline
      • Management Team
      • Board of Directors
      • Careers
      • The Norwegian Transparency Act
    • circRNA
      • Circio AB
      • circVec platform
    • Clinical programs
      • KRAS program
      • Publications
    • Partnering
      • Partnering
    • Investors
      • Warrants exercise 2024
      • Press releases
      • Events
      • Financial calendar
      • Reports
      • Presentations
      • Prospectus
      • Share information
        • Share and trading information
        • Largest shareholders
        • Dividend policy
        • Analyst coverage
        • Registrar and auditor
      • Corporate Governance Policy
      • Code of Conduct
      • Corporate Social Responsibility Principles
      • Remuneration Principles
      • About General Meeting
      • General Meetings
      • Articles of Association
      • Board of Directors
      • Nomination Committee
      • Committees
      • Management
      • Contact
    • Media
      • Press releases
      • Events
      • Subscribe
      • Contact
    • Contacts
      • Offices
      • Investors & Media

    Corporate news

    All press releases
    • Press releases - Regulatory
    • Press releases - Non-regulatory
    • All press releases
    2019
    • 2025
    • 2024
    • 2023
    • 2022
    • 2021
    • 2020
    • 2018
    • 2017
    • 2016
    Corporate news
    • All subjects
    • Other
    November 11, 2019
    Press release - Non-regulatory

    Presentation of ONCOS-102 melanoma data at SITC Annual Meeting

    November 7, 2019
    Press release - Regulatory

    Targovax ASA: Third quarter 2019 results

    October 29, 2019
    Press release - Non-regulatory

    Targovax ASA: Invitation to presentation of Targovax’s third quarter 2019 results, Thursday 7 November

    October 9, 2019
    Press release - Non-regulatory

    Targovax selected for oral presentation at Society for Immunotherapy of Cancer (SITC) 2019 Annual Meeting

    September 24, 2019
    Press release - Non-regulatory

    Targovax announces opening of Oslo University Hospital as site for ONCOS-102 trial in melanoma

    July 31, 2019
    Press release - Non-regulatory

    Targovax is invited to present at Solebury Trout European Biotech Investor Day in NYC

    July 8, 2019
    Press release - Regulatory

    Targovax announces encouraging results from part 1 of the ONCOS-102 and Keytruda combination trial in anti-PD1 refractory melanoma

    June 3, 2019
    Press release - Non-regulatory

    Targovax announces publication of in vivo abscopal effect of ONCOS-102 and Keytruda combination

    May 23, 2019
    Press release - Regulatory

    Targovax to fully focus on ONCOS oncolytic virus program

    May 23, 2019
    Press release - Regulatory

    Targovax announces median and three-year overall survival for TG01 trial in resected pancreatic cancer

    May 9, 2019
    Press release - Regulatory

    Targovax ASA: First quarter 2019 results

    May 8, 2019
    Press release - Non-regulatory

    Targovax announces completed enrollment of ONCOS-102 trial in mesothelioma

    April 30, 2019
    Press release - Regulatory

    Targovax ASA: Minutes from the Annual General Meeting

    April 30, 2019
    Press release - Non-regulatory

    Targovax ASA: Announcement of first quarter 2019

    April 9, 2019
    Press release - Regulatory

    Targovax ASA: Annual Report 2018

    April 9, 2019
    Press release - Regulatory

    Notice of Annual General Meeting

    March 25, 2019
    Press release - Regulatory

    Targovax to hold a webcast with Q&A session

    March 19, 2019
    Press release - Non-regulatory

    Targovax is invited to present at Neoantigen Summit Europe, DNB SME Conference and BIO-Europe Spring

    March 15, 2019
    Press release - Regulatory

    Targovax signs clinical collaboration agreement with the Parker Institute for Cancer Immunotherapy and Cancer Research Institute

    March 14, 2019
    Press release - Non-regulatory

    Targovax grants Zelluna Immunotherapy an FTO license to intellectual property relating to mutant RAS T cell receptor technology

    March 8, 2019
    Press release - Non-regulatory

    Targovax announces Notice of Allowance in the US on patent covering the TG mutant-RAS neoantigen vaccine platform

    February 14, 2019
    Press release - Regulatory

    Targovax ASA: Fourth quarter and full year 2018 results

    February 11, 2019
    Press release - Non-regulatory

    First patient treated in dose expansion cohort of Targovax’s ONCOS-102 trial in melanoma

    February 4, 2019
    Press release - Non-regulatory

    Targovax ASA: Announcement of fourth quarter and full year results 2018

    January 17, 2019
    Press release - Non-regulatory

    Targovax granted European Patent for mutant-RAS neoantigen platform lead products

    IR contact
    Dr Erik Digman Wiklund
    Dr Erik Digman Wiklund
    CEO
    erik.wiklund@circio.com
    (+47) 41 33 35 36
    Dr Lubor Gaal
    Dr Lubor Gaal
    CFO & Head of BD
    lubor.gaal@circio.com
    (+34) 683 343 811
    Circio logo

    Circio Holding ASA is a biotechnology company developing novel circular RNA and immunotherapy medicines.

    • About
    • circRNA
    • Clinical programs
    • Partnering
    • Investors
    • Media
    • Contacts

    CONTACT

    Circio Holding ASA
    Email: contact@circio.com

    • Cookies
    • Privacy policy
    • STAY CONNECTED